October 23rd 2024
Drs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.
October 9th 2024
Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.
September 12th 2024
D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.
July 22nd 2024
Camidge and Kahl reflect on the steps in Kahl’s communications career that paved the way for her to become a leader in the medical journalism field.
July 4th 2024
Camidge and White discuss the intersections between White’s head and neck cancer diagnosis and radiation oncology communications career.
June 13th 2024
Camidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.
May 29th 2024
The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.
May 27th 2024
Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.
May 22nd 2024
The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.
D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.
May 16th 2024
Drs Camidge and Arslan discuss Dr Arslan’s experience providing emergency medical care and the curiosity that led him to pursue a career in industry.
May 15th 2024
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
May 8th 2024
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
May 6th 2024
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.
May 1st 2024
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.